Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer.
Sands JM, Champiat S, Hummel HD, Paulson KG, Borghaei H, Alvarez JB, Carbone DP, Carlisle JW, Choudhury NJ, Clarke JM, Gadgeel SM, Izumi H, Navarro A, Lau SCM, Lammers PE, Huang S, Hamidi A, Mukherjee S, Owonikoko TK.
Sands JM, et al. Among authors: navarro a.
Cancer. 2025 Feb 1;131(3):e35738. doi: 10.1002/cncr.35738.
Cancer. 2025.
PMID: 39876075
Free PMC article.
Review.